David Oh, MD, PhD
Assistant Professor
Medicine
School of Medicine

Clinically, I see patients in the Cancer Immunotherapy Program where I lead numerous early phase trials, with a particular focus on adoptive cell therapies for solid tumors (CAR-T and TCR). I have also led trials of intratumoral immunotherapy and next-generation cytokine therapy.

In the laboratory, I run an extramurally funded translational program focused on the role of cytotoxic immune effectors in anti-tumor responses as well as immune-related adverse events (IRAEs) after immunotherapy. This work spans high-resolution multiomic interrogation and functional validation using patient samples, as well as murine model systems.

• Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
  The Lancet. Oncology 2023 Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong…
• Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.
  Nature medicine 2023 Hassan R, Butler M, O'Cearbhaill RE, Oh DY, Johnson M, Zikaras K, Smalley M, Ross M, Tanyi JL, Ghafoor A, Shah NN, Saboury B, Cao L, Quintás-Cardama A, Hong D
• Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.
  Journal of Clinical Oncology 2023 Raffit Hassan, Marcus O. Butler, David Yoonsuk Oh, Roisin Eilish O'Cearbhaill, Lauren MacMullen, Erin Jeter, Udayan Guha, Viera P. Muzithras, Kevin Zikaras, Melissa Lynne Johnson, Janos Laszlo Tanyi, …
• Non-viral precision T cell receptor replacement for personalized cell therapy.
  Nature 2022 Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, Yuen B, Dalmas O, Heeringa K, Sennino B, Conroy A, Bethune MT, Mende I, White W, Kukreja M, Gunturu S, Humphrey E, …
• Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer.
  Science immunology 2022 Kwon H, Schafer JM, Song NJ, Kaneko S, Li A, Xiao T, Ma A, Allen C, Das K, Zhou L, Riesenberg B, Chang Y, Weltge P, Velegraki M, Oh DY, Fong L, Ma Q, Sundi D, Chung D, Li X, Li Z
• Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).
  Journal of Clinical Oncology 2022 Susan F. Slovin, Tanya B. Dorff, Gerald Steven Falchook, Xiao X. Wei, Xin Gao, Rana R. McKay, David Yoonsuk Oh, Andreas Georg Wibmer, Matthew A. Spear, Joanne McCaigue, Devon J. Shedlock, Manjima Dhar…
• Preparation of Radiolabeled Antibodies for Nuclear Medicine Applications in Immuno-Oncology.
  Methods in molecular biology (Clifton, N.J.) 2022 Wei J, Oh DY, Evans MJ
• Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox.
  Immunity 2021 Oh DY, Fong L
• Toward a better understanding of T cells in cancer.
  Cancer cell 2021 Oh DY, Fong L, Newell EW, Turk MJ, Chi H, Chang HY, Satpathy AT, Fairfax B, Silva-Santos B, Lantz O
• In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET.
  ACS central science 2021 Zhao N, Bardine C, Lourenço AL, Wang YH, Huang Y, Cleary SJ, Wilson DM, Oh DY, Fong L, Looney MR, Evans MJ, Craik CS
• Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy.
  Anticancer research 2021 Keenan BP, VAN Loon K, Khilnani AD, Fidelman N, Behr SC, Atreya CE, Oh DY
• An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer.
  Journal of Clinical Oncology 2021 Apostolia Maria Tsimberidou, Alexandra Drakaki, Danny Khalil, Shivaani Kummar, F. Stephen Hodi, David Yoonsuk Oh, Christopher R. Cabanski, Michael Tezlaff, Theresa LaVallee, Marko Spasic, Leo Nissola,…
• Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423).
  Journal of Clinical Oncology 2021 Divya V Natesan, Li Zhang, David Yoonsuk Oh, Sima P. Porten, Maxwell Meng, Raj Pruthi, Matthew R. Cooperberg, Peter Carroll, Jonathan Chou, Hala Borno, Rohit Bose, Arpita Desai, Daniel H Kwon, Anthony…
• TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
  Journal for immunotherapy of cancer 2021 de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, …
• Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
  Clinical science (London, England : 1979) 2021 Baik AH, Tsai KK, Oh DY, Aras MA
• CD38 as a Novel Immunosuppressive Target in Prostate Cancer.
  European urology 2021 Oh DY
• Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy.
  Journal of Clinical Oncology 2021 Vadim S Koshkin, Divya Natesan, Li Zhang, David Yoonsuk Oh, Sima P. Porten, Maxwell Meng, Raj Pruthi, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander
• TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors.
  Journal of Clinical Oncology 2021 Ivan de Kouchkovsky, Li Zhang, Errol Philip, Francis Wright, Daniel Myung Kim, Divya Natesan, Daniel Kwon, Hansen Ho, Son Ho, Emily Chan, Sima P. Porten, Arpita Desai, Franklin W. Huang, Jonathan Chou…
• Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.
  Cancer immunology, immunotherapy : CII 2021 Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L
• Autoantibody Landscape in Patients with Advanced Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M…
• Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.
  Cancer immunology research 2020 Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L
• An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.
  Molecular imaging and biology 2020 Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ
• Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.
  Cell 2020 Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L
• Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
  Journal for immunotherapy of cancer 2020 Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L
• Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer.
  Journal of Clinical Oncology 2020 Errol James Philip, Francis Wright, Daniel Myung Kim, Daniel Kwon, Hansen Ho, Son Ho, Edna Cheung, Emily Chan, Sima P. Porten, Anthony C. Wong, Hala Borno, Arpita Desai, Jonathan Chou, David Yoonsuk …
• Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations.
  Journal of Clinical Oncology 2020 Daniel Kwon, Francis Wright, Li Zhang, Jonathan Chou, Hala Borno, Arpita Desai, David Yoonsuk Oh, YaoYao Guan Pollock, Rohit Bose, Franklin W. Huang, Thomas Hope, Terence W. Friedlander, Lawrence Fong…
• TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer.
  Frontiers in immunology 2020 Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L
• Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
  Digestive diseases and sciences 2019 Hammami MB, Gill R, Thiruvengadam N, Oh DY, Beck K, Mahadevan U, Kattah MG
• Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
  Immunity 2019 Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R…
• Immunity in the Time of Metastases.
  Immunity 2018 Oh DY, Fong L
• Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer.
  Oncoimmunology 2018 Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L
• Abstract 4688: Single-cell discrimination of altered human T cell states in the bladder tumor microenvironment.
  Immunology 2018 David Yoonsuk Oh, Serena S. Kwek, Serghei Mangul, Siddharth S. Raju, Sasha Targ, Arun Burra, Eric Chow, Dvir Aran, Sima Porten, Maxwell V. Meng, Terence W. Friedlander, Chun Jimmie Ye, Lawrence Fong
• Abstract 1694: Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment increases T cell receptor diversity in localized and metastatic prostate cancer patients.
  Immunology 2017 David Y. Oh, Li Zhang, Jason Cham, Alan Paciorek, Mark Klinger, Malek Faham, Susan F. Slovin, Lawrence Fong
• Abstract 549: Clustering analysis of next-generation sequencing T cell repertoire data in sipuleucel-T treated prostate cancer patients.
  Bioinformatics and Systems Biology 2017 Li Zhang, Sounak Chakraborty, Jason Cham, David Oh, Nadeem Sheikh, Lawrence Fong
• Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
  Cancer Res. 2017 Oh DY,* Cham J,* Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. *co-first author.
• Abstract 4362: T cell repertoire diversification is associated with immune related toxicities following immune checkpoint inhibition in metastatic cancer patients.
  Immunology 2016 David Y. Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, Lawrence Fong
• Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients.
  Journal of Clinical Oncology 2016 David Yoonsuk Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, Lawrence Fong
• On the Verge: Immunotherapy for Colorectal Carcinoma.
  Journal of the National Comprehensive Cancer Network : JNCCN 2015 Oh DY, Venook AP, Fong L
• Differential contribution of chemotaxis and substrate restriction to segregation of immature and mature thymocytes
  Immunity. 2009 Ehrlich LI,* Oh DY,* Weissman IL, Lewis RS. *co-first author.
• Calcium oscillations regulate thymocyte motility during positive selection in the three-dimensional thymic environment.
  Nature immunology 2005 Bhakta NR, Oh DY, Lewis RS
• Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor.
  Cell 2003 Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J
• Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks.
  The Journal of biological chemistry 2001 Beresford PJ, Zhang D, Oh DY, Fan Z, Greer EL, Russo ML, Jaju M, Lieberman J
• A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation
  J Immunol. 2000 Gommerman JL,* Oh DY,* Zhou X, Tedder TF, Maurer M, Galli SJ, Carroll MC. *co-first author.